Arcutis Biotherapeutics (ARQT) announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older. The approval of ZORYVE foam 0.3% for seborrheic dermatitis in Canada was supported by results from a vehicle-controlled pivotal Phase 3 study, as well as a Phase 2 study, a long-term open-label extension study, and a Phase 1 pharmacokinetic study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis announces new pooled subgroup analysis results from INTEGUMENT-1 trial
- Arcutis Biotherapeutics announces FDA accepted its sNDA for ZORYVE foam
- Arcutis Biotherapeutics annonnces publication of ZORYVE in JAMA Dermatology
- Arcutis Biotherapeutics completes enrollment of Phase 1b study on ARQ-255
- Arcutis announces results from INTEGUMENT-OLE study of roflumilast cream